Stocktoria
KYNTRA BIO, INC. KYNB
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2014-11-14
KYNTRA BIO, INC. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.4M | $29.6M | $46.8M | $140.7M | $235.3M | $176.3M | $256.6M | $213.0M | $131.0M | $183.2M |
| R&D expense | $23.5M | $95.7M | $266.5M | $296.8M | $387.0M | $252.9M | $209.3M | $235.8M | $196.5M | $187.2M |
| SG&A expense | $27.7M | $49.3M | $86.5M | $124.7M | $123.9M | $106.4M | $135.5M | $63.8M | $51.8M | — |
| Operating income | -$45.9M | -$150.4M | -$322.7M | -$301.0M | -$288.5M | -$191.9M | -$89.3M | -$86.7M | -$117.3M | -$50.0M |
| Interest expense | $8.8M | $8.2M | $8.1M | $1.4M | $1.1M | $2.4M | $2.9M | $11.0M | $9.7M | $10.7M |
| Income tax | -$90,000 | -$269,000 | -$252,000 | $358,000 | $347,000 | $360,000 | $328,000 | $304,000 | $321,000 | -$71,000 |
| Net income | $183.5M | -$47.6M | -$284.2M | -$293.7M | -$290.0M | -$189.3M | -$77.0M | -$86.4M | -$120.9M | -$58.1M |
| EPS (diluted) | $45.37 | $-11.89 | $-2.92 | $-3.14 | $-3.14 | $-2.11 | — | — | — | — |
| Operating cash flow | -$4.8M | -$138.0M | -$315.0M | -$145.9M | -$82.2M | $81.6M | -$78.7M | -$76.1M | -$66.5M | $7.1M |
| Free cash flow | -$4.8M | -$138.3M | -$317.5M | -$149.7M | -$87.4M | $77.6M | -$84.5M | -$84.2M | -$75.0M | $5.9M |
| Cash & equivalents | $47.9M | $50.5M | $81.6M | $155.7M | $171.2M | $678.4M | $126.3M | $89.3M | $673.7M | $173.8M |
| Inventory | $3.7M | $3.2M | $17.2M | $40.4M | $31.0M | $16.5M | $6.9M | $0 | — | — |
| Total assets | $119.6M | $214.5M | $423.5M | $610.1M | $773.8M | $826.8M | $857.4M | $880.6M | $898.6M | $469.6M |
| Total liabilities | $115.1M | $398.2M | $585.7M | $611.6M | $544.7M | $385.4M | $322.0M | $352.1M | $350.9M | $294.4M |
| Shareholders' equity | -$30.0M | -$225.6M | -$204.2M | -$21.4M | $229.1M | $441.4M | $535.4M | $528.5M | $547.7M | $155.8M |
Growth · year-over-year · Revenue CAGR -31.1%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -78.3% | -36.7% | -66.7% | -40.2% | +33.5% | -31.3% | +20.5% | +62.6% | -28.5% | +1.3% |
| Free cash flow growth | — | — | — | — | -212.6% | — | — | — | -1381.0% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.